All News

Litigation, Launch, and Lower Costs: 3 Big Moves in the US Biosimilar Space

August 19th 2025

By Skylar Jeremias

Explore groundbreaking developments in biosimilars, including patent lawsuits, new ustekinumab launches, and innovative access strategies for patients.

The Top 5 Biosimilar Articles for the Week of August 11

August 15th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 11, 2025.

Denosumab Biosimilar LY01011 Shows Equivalence to Reference Product for Bone Metastases

August 14th 2025

By Cameron Santoro

Article

Biosimilar LY01011 is equivalent to the reference product denosumab for treating bone metastases in solid tumors, demonstrating similar efficacy in reducing bone metabolism biomarkers, comparable safety profiles, and a lack of unexpected adverse reactions.

Biosimilar Business Recap: Updates on Tocilizumab, Omalizumab, and Ranibizumab Products

August 13th 2025

By Skylar Jeremias

Article

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ranibizumab.

Japanese Study Provides Postapproval Insights Into Biosimilar Quality Attributes

August 12th 2025

By Skylar Jeremias

Article

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and public confidence in these therapies.

Low Prices Fail to Boost Insulin Biosimilar Uptake in the UK

August 11th 2025

By Skylar Jeremias

Article

Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia despite regulatory support and cost-saving potential.

The Top 5 Biosimilar Articles for the Week of August 4

August 8th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 4, 2025.

Dulaglutide Biosimilar LY05008 Shows Efficacy and Safety in Treating Type 2 Diabetes

August 7th 2025

By Cameron Santoro

Article

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults with type 2 diabetes.

Year-Long Phase 3 Study Confirms Tocilizumab Biosimilar Comparability With Actemra

August 6th 2025

By Skylar Jeremias

Article

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis treatment, enhancing access and affordability.

Postmarketing Surveillance Data Reinforce Trastuzumab Biosimilar Safety in HER2+ Gastric Cancer

August 5th 2025

By Deana Ferreri, PhD

Article

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.